SignPath Pharma, Inc. - FORM 10-K - EX-10.6 - AMENDMENT DATED APRIL 12, 2012 TO THE LIPSOMAL FOUNDATION MANUFACTURING AGREEMENT WITH POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORCHUNG GMBH. - April 9, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - SignPath Pharma, Inc.Financial_Report.xls
EX-4.9 - FORM OF CLASS D COMMON STOCK PURCHASE WARRANT - SignPath Pharma, Inc.signpathexh49.htm
EX-4.10 - FORM OF SERIES D SUBSCRIPTION AGREEMENT - SignPath Pharma, Inc.signpathexh410.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - SignPath Pharma, Inc.signpathexh311.htm
EX-10.7 - AMENDMENT, DATED AUGUST 23, 2012, TO THE LIPOSOMAL FORMULATION MANUFACTURING AGREEMENT WITH POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH. - SignPath Pharma, Inc.signpathexh107.htm
EX-10.9 - EXCLUSIVE LICENSE AGREEMENT, DATED JUNE 5, 2013, WITH JOHNS HOPKINS UNIVERSITY. - SignPath Pharma, Inc.signpathexh109.htm
EX-10.16 - AMENDMENT NO. 1, DATED JULY 18, 2014, TO THE SPONSORED RESEARCH AGREEMENT BY AND BETWEEN THE REGISTRANT AND UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH DATED AUGUST 1, 2013. - SignPath Pharma, Inc.signpathexh1016.htm
EX-10.17 - AMENDMENT NO. 1, DATED DECEMBER 12, 2014, TO THE EMPLOYMENT AGREEMENT BY AND BETWEEN THE REGISTRANT AND DR. LAWRENCE HELSON. - SignPath Pharma, Inc.signpathexh1017.htm
EX-10.11 - PATENT AND TECHNOLOGY LICENSE AGREEMENT DATED NOVEMBER 25, 2015, BETWEEN THE REGISTRANT AND THE UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER. - SignPath Pharma, Inc.signpathexh1011.htm
EX-10.15 - SPONSORED RESEARCH AGREEMENT BY AND BETWEEN THE REGISTRANT AND UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH DATED AUGUST 1, 2013. - SignPath Pharma, Inc.signpathexh1015.htm
EX-10.12 - PLACEMENT AGENCY AGREEMENT DATED AS OF SEPTEMBER 17, 2014 BY AND BETWEEN SIGNPATH PHARMA INC. AND MEYERS ASSOCIATES L.P. - SignPath Pharma, Inc.signpathexh1012.htm
10-K - SIGHPATH PHARMA 10K 2014-12-31 - SignPath Pharma, Inc.signpath.htm
EX-32.1 - CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. - SignPath Pharma, Inc.signpathexh321.htm
Exhibit 10.6
Amendment II
to the Agreement for the Manufacturing  of a Liposomal Formulation


between

SignPath Pharma, Inc. ("SIGNPATH")
1375 California RD,Quakertown, PA 18951, USA

and

Polymun Scientific Immunbiologische Forschung GmbH ("POLYMUN")
Donaustr. 99, 3400 Klosterneuburg, Austria

Pursuant to § 11.6. of the Agreement between SIGNPATH and POLYMUN from 6th  of September 2007, which stipulates that "Modifications/amendments to or extensions of this Agreement are only valid if in writing and signed for and on behalf of both parties.", SIGNPATH and POLYMUN hereby acknowledge the following Amendment to the Agreement:

SIGNPATH is sponsor of a first in man study with liposomal curcumin in Vienna. Pursuant to the first Amendment to the Agreement from 10th of November 2011, POLYMUN is acting as legal representative for  this study in connection with  overall study management. The study will be substantially amended to  include 20 additional subjects for higher doses of liposomal curcumin.
 
The Subject Matter of Agreement  will be amended for the following additional  services
 

Task
Price
Study Amendment Preparation
Study protocol version V04
 
 
 
 
 
 
 
 
€ 8.000
Ethic application form
EudraCT application form
Patient information
Investigator's brochure (review)
Management
Coordination activity with SIGNPATH, CRO of study, analytical laboratory (Nucro), clinical site, safety board, ethics committee, regulatory authority (AGES PharmMed)
€ 15.000
Continuation as Legal Representative
Legal representative (fee)
€ 7.000
 
Page 1of 2
 
 
 
 
 
Payment schedule
 
•      25% of the costs at signing of this Amendment
 
•      25% of the costs at first patient in
 
•      50% of the costs at last patient out
 
Phase 1b study in cancer Patients with CESAR (Central European Society for Anticancer
 

Drug Research-EWIV)
Protocol development support and project coordination by Dr. Brigitta Vcelar                         I           € 115 per hour
 
Payment schedule
 
•      Written approval by SIGNPATH of maximal amount of hours in advance for each calendar quarter
 
 Written approval by SIGNPATH of additional amount of hours in case of previously approved amount of hours not sufficient
 
•      Invoices per calendar quarter with tabulated form of hours spent on protocol development support by Dr. Brigitta Vcelar with summary of activities

Not included:
 
•      Fees of regulatory authorities
 
•      Fees of ethics committee
 
•      Costs of patient insurance
 
•      Print of paper CRFs
 
•      Costs of sample shipment

The term of the Agreement defined in §4.1. of the Agreement will be extended until 31st of December 2013.


For SIGNPATH:                                                                                   For POLYMUN:


/s/ Lawrence Helson, MD                                                                                   /s/ Dr. Dietmar Katinger                                                    12.04.2012
Lawrence Helson, MD, CEO                                                                                   Dr. Dietmar Katinger, CEO


 

 


Page 2 of 2
 
 

SignPath Pharma, Inc. Reports